These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10911385)

  • 1. Prolonged complete remission of myelodysplastic syndrome treated with danazol, retinoic acid and low-dose prednisone.
    Sadek I; Zayed E; Hayne O; Fernandez L
    Am J Hematol; 2000 Aug; 64(4):306-10. PubMed ID: 10911385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
    Guan M; Chen SC; Li RS; Ge CW; Zhu HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid.
    Letendre L; Levitt R; Pierre RV; Schroeder G; Krook JA; Mailliard JE; Morton RF; Tschetter LK
    Am J Hematol; 1995 Apr; 48(4):233-6. PubMed ID: 7717370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoplastic myelodysplastic syndrome.
    Nand S; Godwin JE
    Cancer; 1988 Sep; 62(5):958-64. PubMed ID: 3409176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
    Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
    Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Danazol as First-Line Therapy for Myelodysplastic Syndrome.
    Colunga-Pedraza PR; Colunga-Pedraza JE; Garza-Ledezma MA; Jaime-Pérez JC; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Rendón-Ramírez EJ; López-García YK; Lozano-Morales RE; Gómez-De León A; Sotomayor-Duque G; Gómez-Almaguer D
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e109-e113. PubMed ID: 29268959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of transformed myelodysplastic syndrome with fibrosis after danazol therapy.
    Damaj G; Lefrère F; Canioni D; Rubio MT; Radford-Weiss I; Valensi F; Varet B; Hermine O
    Eur J Haematol; 2002 Apr; 68(4):233-5. PubMed ID: 12071939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective observation of curative effects on MDS refractory anemia with combination of all-trans retinoic acid, 1, 25-dihydroxyvitamin D3 and androgen].
    Zhou FL; Zhang WG; Cao XM; Chen YX; He AL; Liu J; Zhao WH; Ma XR; Chen G
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):861-6. PubMed ID: 16277859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
    Kuendgen A; Strupp C; Aivado M; Bernhardt A; Hildebrandt B; Haas R; Germing U; Gattermann N
    Blood; 2004 Sep; 104(5):1266-9. PubMed ID: 15155466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study.
    Aul C; Runde V; Gattermann N
    Blood; 1993 Nov; 82(10):2967-74. PubMed ID: 8219188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
    Feng FE; Feng R; Wang M; Zhang JM; Jiang H; Jiang Q; Lu J; Liu H; Peng J; Hou M; Shen JL; Wang JW; Xu LP; Liu KY; Huang XJ; Zhang XH
    Lancet Haematol; 2017 Oct; 4(10):e487-e496. PubMed ID: 28917657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Terzoli E; Amadori S
    Blood; 2002 Mar; 99(5):1578-84. PubMed ID: 11861271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
    Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N
    Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.
    Yilmaz A; Kaufmann CC; Binder C; Wörmann B; Haase D
    Ann Hematol; 2001 Jan; 80(1):53-7. PubMed ID: 11233778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.